QUINTILES: The New Health

The survey includes some interesting data on different perspectives about Big Pharma business development activities.

Biopharma companies are under relentless pressure to increase speed and productivity, streamline
development processes without sacrificing safety, ethics and stewardship, and create better value and greater accessibility for patients worldwide.



To do that, they must focus on four key platforms for change:

>>Demonstrating value

>>Increasing productivity

>>Accelerating timelines

>>Overcoming complexity

Including this nugget: To the question, “What is the impact of large biopharma mergers on innovation?”

53% of biopharma execs said they reduce opportunities for innovation, versus only

15% who see mega-merger as improving innovation; on the other hand,

39% of managed care executives see mega-mergers as improving opportunities for innovation, versus

37% who see them reduced.

In other words, more managed care executives seem to be believe that consolidation in the Big Pharma sector will improve R&D productivity than do biopharma execs.



Descargar informe